---

WHO CNS 5 and meningiomas: What’s new?

---

Review Article

Author Details : Indranil Chakrabarti*, Sujaya Mazumder

Volume : 9, Issue : 2, Year : 2024

Article Page : 67-71

https://doi.org/10.18231/j.achr.2024.015

Suggest article by email

Get Permission

---

Abstract

Meningiomas are the most common primary intracranial tumors in adults comprising about one-third of cases. Most of them are slow-growing and follow a benign course. However, some may behave aggressively with recurrence and even metastasis. Histopathological features have long been regarded as the gold standard for diagnosis, grading, and prognostication. Advances in genomics and molecular characteristics of meningiomas have uncovered the potential use of many biomarkers for more accurate grading and prediction of prognosis and recurrence. Precision clinical trials are needed to utilize these biomarkers for targeted therapy. The present review is a snapshot of some of these important updates in meningioma as per the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5).
 

Keywords: Meningiomas, WHO CNS 5, Molecular markers

How to cite : Chakrabarti I, Mazumder S, WHO CNS 5 and meningiomas: What’s new?. IP Arch Cytol Histopathol Res 2024;9(2):67-71

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.